Search research articles
Contact Us
Filters
Showing results (171-180 of 194) with videos related to
Page
of 20
Sort By:
Therapeutic Advances in Hematology
|
April 4, 2022
A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy
Guangxin Peng, Guangsheng He, Hong Chang, et al.
European Journal of Clinical Pharmacology
|
May 1, 2019
Relationship between warfarin dosage and international normalized ratio: a dose-response analysis and evaluation based on multicenter data
Ling Xue, Yuzhen Zhang, Cheng Xie, et al.
The Lancet. Haematology
|
June 30, 2022
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
Yuqin Song, Yanyan Liu, Zhi-Ming Li, et al.
Nature Communications
|
April 25, 2024
Ice sheet and precession controlled subarctic Pacific productivity and upwelling over the last 550,000 years
Zhengquan Yao, Xuefa Shi, Qiuzhen Yin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 9, 2020
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
Yun Fan, Jun Zhao, Qiming Wang, et al.
Drug Design, Development and Therapy
|
April 8, 2020
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia
Jason D Lickliter, Hui K Gan, Mark Voskoboynik, et al.
JAMA Oncology
|
January 2, 2026
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial
Xinan Sheng, Gang Huang, Meiyu Fang, et al.
BMC Medicine
|
December 27, 2022
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
Jiong Wu, Zefei Jiang, Zhenzhen Liu, et al.
Cancer Immunology, Immunotherapy : CII
|
October 20, 2021
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study
Jin-Ji Yang, Cheng Huang, Yun Fan, et al.
BMC Medicine
|
January 18, 2022
PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study
Mingtong Xu, Xiaoxue Zhu, Junyan Wu, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 194) with videos related to
Sort By:
Page
of 20
Therapeutic Advances in Hematology
|
April 4, 2022
A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy
Guangxin Peng, Guangsheng He, Hong Chang, et al.
European Journal of Clinical Pharmacology
|
May 1, 2019
Relationship between warfarin dosage and international normalized ratio: a dose-response analysis and evaluation based on multicenter data
Ling Xue, Yuzhen Zhang, Cheng Xie, et al.
The Lancet. Haematology
|
June 30, 2022
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
Yuqin Song, Yanyan Liu, Zhi-Ming Li, et al.
Nature Communications
|
April 25, 2024
Ice sheet and precession controlled subarctic Pacific productivity and upwelling over the last 550,000 years
Zhengquan Yao, Xuefa Shi, Qiuzhen Yin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 9, 2020
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
Yun Fan, Jun Zhao, Qiming Wang, et al.
Drug Design, Development and Therapy
|
April 8, 2020
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia
Jason D Lickliter, Hui K Gan, Mark Voskoboynik, et al.
JAMA Oncology
|
January 2, 2026
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial
Xinan Sheng, Gang Huang, Meiyu Fang, et al.
BMC Medicine
|
December 27, 2022
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
Jiong Wu, Zefei Jiang, Zhenzhen Liu, et al.
Cancer Immunology, Immunotherapy : CII
|
October 20, 2021
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study
Jin-Ji Yang, Cheng Huang, Yun Fan, et al.
BMC Medicine
|
January 18, 2022
PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study
Mingtong Xu, Xiaoxue Zhu, Junyan Wu, et al.
Page
of 20